{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:17:06Z","timestamp":1773274626339,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04656-1","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:46:45Z","timestamp":1770454005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia"],"prefix":"10.1186","volume":"26","author":[{"given":"Getachew Bizuneh","family":"Aydagnuhm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aklile Semu","family":"Tefera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gebru Tesfaw","family":"Getahun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermiyas Endewunet","family":"Melaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"3","key":"4656_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"W-K Chan","year":"2023","unstructured":"Chan W-K, Chuah K-H, Rajaram RB, Lim L-L, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metabolic Syndrome. 2023;32(3):197.","journal-title":"J Obes Metabolic Syndrome"},{"issue":"3","key":"4656_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s42000-022-00377-8","volume":"21","author":"S Kechagias","year":"2022","unstructured":"Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones. 2022;21(3):349\u201368.","journal-title":"Hormones"},{"issue":"4","key":"4656_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","volume":"17","author":"D Liver EAftSot","year":"2024","unstructured":"Liver EAftSot D, EAftSo. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17(4):374\u2013444.","journal-title":"Obes Facts"},{"issue":"6","key":"4656_CR4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"8","key":"4656_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao Y-Y, Zheng M-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metabolism. 2024;35(8):697\u2013707.","journal-title":"Trends Endocrinol Metabolism"},{"issue":"Suppl","key":"4656_CR6","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024;31(Suppl):S32.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4656_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"3","key":"4656_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"1","key":"4656_CR9","doi-asserted-by":"publisher","first-page":"100774","DOI":"10.1016\/j.aohep.2022.100774","volume":"28","author":"L Torres","year":"2023","unstructured":"Torres L, Schuch A, Longo L, Valentini BB, Galv\u00e3o GS, Luchese E, et al. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD. Ann Hepatol. 2023;28(1):100774.","journal-title":"Ann Hepatol"},{"issue":"12","key":"4656_CR10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(21)00275-2","volume":"6","author":"CW Spearman","year":"2021","unstructured":"Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, et al. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2021;6(12):1036\u201346.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"4656_CR11","doi-asserted-by":"publisher","first-page":"e0002835","DOI":"10.1371\/journal.pgph.0002835","volume":"4","author":"E Ekpor","year":"2024","unstructured":"Ekpor E, Akyirem S, Adade Duodu P. Prevalence of metabolic dysfunction-associated fatty liver disease and its association with glycemic control in persons with type 2 diabetes in africa: A systematic review and meta-analysis. PLOS Global Public Health. 2024;4(5):e0002835.","journal-title":"PLOS Global Public Health"},{"key":"4656_CR12","doi-asserted-by":"publisher","first-page":"1506032","DOI":"10.3389\/fgstr.2025.1506032","volume":"4","author":"EM Sindato","year":"2025","unstructured":"Sindato EM, Kajogoo VD, Ngajilo G, Degu WA, Khan Z, Mlawa G. Prevalence and risk factors of metabolic-associated fatty liver disease in sub-Saharan africa: a systematic review and meta-analysis. Front Gastroenterol. 2025;4:1506032.","journal-title":"Front Gastroenterol"},{"issue":"1","key":"4656_CR13","doi-asserted-by":"publisher","first-page":"5555842","DOI":"10.1155\/jdr\/5555842","volume":"2025","author":"EA Berhe","year":"2025","unstructured":"Berhe EA, Sema RA, Tesfaye YM, Berhane AA, Dawit M, Gebrehiwot EM, et al. Assessing nonalcoholic fatty liver disease in type 2 diabetes patients at a tertiary Hospital, addis Ababa, Ethiopia. J Diabetes Res. 2025;2025(1):5555842.","journal-title":"J Diabetes Res"},{"key":"4656_CR14","unstructured":"Organization WH. Obesity: preventing and managing the global epidemic: report of a WHO consultation. 2000."},{"key":"4656_CR15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc23-Sint","volume":"46","author":"D Care","year":"2023","unstructured":"Care D. Standards of care in diabetes\u20142023. Diabetes Care. 2023;46:S1\u2013267.","journal-title":"Diabetes Care"},{"issue":"1","key":"4656_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","volume":"79","author":"A Al-Makki","year":"2022","unstructured":"Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, et al. Hypertension Pharmacological treatment in adults: a world health organization guideline executive summary. Hypertension. 2022;79(1):293\u2013301.","journal-title":"Hypertension"},{"key":"4656_CR17","volume-title":"Harrison\u2019s principles of internal medicine","author":"A Fauci","year":"2022","unstructured":"Fauci A, Longo D, Kasper D, Jameson J, Loscalzo J, Hauser S. Harrison\u2019s principles of internal medicine. New York: McGraw Hill Medical;: Twenty; 2022."},{"issue":"11","key":"4656_CR18","first-page":"955","volume":"12","author":"J-G Fan","year":"2024","unstructured":"Fan J-G, Xu X-Y, Yang R-X, Nan Y-M, Wei L, Jia J-D, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024). J Clin Translational Hepatol. 2024;12(11):955.","journal-title":"J Clin Translational Hepatol"},{"issue":"4","key":"4656_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s13244-014-0336-2","volume":"5","author":"J Gerstenmaier","year":"2014","unstructured":"Gerstenmaier J, Gibson R. Ultrasound in chronic liver disease. Insights into Imaging. 2014;5(4):441\u201355.","journal-title":"Insights into Imaging"},{"issue":"15","key":"4656_CR20","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.3390\/jcm11154581","volume":"11","author":"G Petzold","year":"2022","unstructured":"Petzold G. Role of ultrasound methods for the assessment of NAFLD. J Clin Med. 2022;11(15):4581.","journal-title":"J Clin Med"},{"issue":"5","key":"4656_CR21","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"7","key":"4656_CR22","first-page":"477","volume":"101","author":"FC Kruger","year":"2011","unstructured":"Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, Van Rensburg C, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH. South Afr Med J. 2011;101(7):477\u201380.","journal-title":"South Afr Med J"},{"issue":"2","key":"4656_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/ajg.2017.469","volume":"113","author":"AK Singal","year":"2018","unstructured":"Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. Official J Am Coll Gastroenterology| ACG. 2018;113(2):175\u201394.","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"issue":"6","key":"4656_CR24","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","volume":"22","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the united states: NHANES 2017\u20132020. Clin Gastroenterol Hepatol. 2024;22(6):1330\u20132. e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4656_CR25","doi-asserted-by":"crossref","unstructured":"Penmetsa R, Kapil S, VanWagner LB. Sex and gender differences in metabolic dysfunction-associated liver disease. Indian J Gastroenterol. 2025:1\u201310.","DOI":"10.1007\/s12664-025-01833-0"},{"issue":"2","key":"4656_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/life14020272","volume":"14","author":"S Cernea","year":"2024","unstructured":"Cernea S. NAFLD fibrosis progression and type 2 diabetes: the hepatic\u2013metabolic interplay. Life. 2024;14(2):272.","journal-title":"Life"},{"issue":"2","key":"4656_CR27","doi-asserted-by":"publisher","first-page":"e0171502","DOI":"10.1371\/journal.pone.0171502","volume":"12","author":"EH van den Berg","year":"2017","unstructured":"van den Berg EH, Amini M, Schreuder TC, Dullaart RP, Faber KN, Alizadeh BZ, et al. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: a large Dutch population cohort. PLoS ONE. 2017;12(2):e0171502.","journal-title":"PLoS ONE"},{"issue":"11","key":"4656_CR28","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"EEL Cho","year":"2023","unstructured":"Cho EEL, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138\u201348.","journal-title":"Gut"},{"key":"4656_CR29","doi-asserted-by":"crossref","unstructured":"Joo SK, Kim W. Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review. Ewha Med J. 2024;47(2).","DOI":"10.12771\/emj.2024.e17"},{"issue":"4","key":"4656_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"issue":"4","key":"4656_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction\u2010associated steatotic liver disease in the middle East and North Africa. Liver Int. 2024;44(4):1061\u201370.","journal-title":"Liver Int"},{"issue":"1","key":"4656_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12967-023-04047-0","volume":"21","author":"S Lu","year":"2023","unstructured":"Lu S, Xie Q, Kuang M, Hu C, Li X, Yang H, et al. Lipid metabolism, BMI and the risk of nonalcoholic fatty liver disease in the general population: evidence from a mediation analysis. J Translational Med. 2023;21(1):192.","journal-title":"J Translational Med"},{"issue":"5","key":"4656_CR33","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1111\/ijpo.70003","volume":"20","author":"M Sun","year":"2025","unstructured":"Sun M, Sun H. Recent prevalence and trends of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) among US adolescents: 1999 to 2020. Pediatr Obes. 2025;20(5):e70003.","journal-title":"Pediatr Obes"},{"issue":"1","key":"4656_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12876-025-03780-8","volume":"25","author":"T Ichikawa","year":"2025","unstructured":"Ichikawa T, Hashimoto Y, Okamura T, Obora A, Kojima T, Okada H, et al. Relationship between anthropometric measures and the risk of incident metabolic dysfunction-associated steatotic liver disease: a longitudinal study. BMC Gastroenterol. 2025;25(1):202.","journal-title":"BMC Gastroenterol"},{"key":"4656_CR35","doi-asserted-by":"crossref","unstructured":"Yeo YH, Zhu Y, Gao J, Liu S, Ni W, Rui F, et al. Anthropometric measures and mortality risk in individuals with metabolic Dysfunction-Associated steatotic liver disease (MASLD): A Population\u2010Based cohort study. Alimentary Pharmacology & Therapeutics; 2025.","DOI":"10.1111\/apt.70174"},{"issue":"10","key":"4656_CR36","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.3390\/jcm14103405","volume":"14","author":"R Bende","year":"2025","unstructured":"Bende R, Heredea D, Ra\u021biu I, Sporea I, D\u0103nil\u0103 M, \u0218irli R, et al. Association between visceral adiposity and the prediction of hepatic steatosis and fibrosis in patients with metabolic Dysfunction-Associated steatotic liver disease (MASLD). J Clin Med. 2025;14(10):3405.","journal-title":"J Clin Med"},{"key":"4656_CR37","doi-asserted-by":"publisher","first-page":"e77772","DOI":"10.2196\/77772","volume":"10","author":"AM Elnasieh","year":"2025","unstructured":"Elnasieh AM, Almesned M, Al Hazmi AN, Alturki A, Alhawaidi FI, Alhadlq RK, et al. Prevalence and risk factors of metabolic Dysfunction\u2013Associated steatotic liver disease in patients with type 2 diabetes mellitus at a tertiary center in Saudi arabia: Cross-Sectional questionnaire study. JMIR Diabetes. 2025;10:e77772.","journal-title":"JMIR Diabetes"},{"issue":"1","key":"4656_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.21608\/smj.2025.349381.1522","volume":"29","author":"GM Galal","year":"2025","unstructured":"Galal GM, Gamal W, Abdel-Gawad AR, Maher A. Body composition analysis as an indicator of steatosis severity in metabolic Dysfunction-associated steatotic liver disease (Formerly known as Non-Alcoholic fatty liver disease): A Cross-Sectional study. Sohag Med J. 2025;29(1):197\u2013211.","journal-title":"Sohag Med J"},{"issue":"1","key":"4656_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12876-025-03786-2","volume":"25","author":"Q-Q Wang","year":"2025","unstructured":"Wang Q-Q, Zhang N, Xu X, Lv S-A, Huang Z-D, Long X-D, et al. The role of triglyceride Glucose-Waist circumference (TyG_WC) in predicting metabolic dysfunction-associated steatotic liver disease among individuals with hyperuricemia. BMC Gastroenterol. 2025;25(1):220.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04656-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:55:33Z","timestamp":1773222933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04656-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4656"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04656-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study will was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and the National Research Ethics Review Guidelines of Ethiopia. Ethical approval was sought from the Institutional Review Board (IRB) of Asrat Woldeyes Health Science Campus, Debre Berhan University (DBU) with reference number 410 prior to commencing the study.A formal letter of cooperation and permission was also obtained from the administrative offices of the selected hospitals. All participants were fully informed about the objectives, procedures, potential benefits, and risks of the study. Written informed consent was obtained from each participant before enrollment. For participants who are illiterate, the consent form was read to them in a language they understood, and a thumbprint was collected in the presence of an impartial witness. Participants with findings indicative of metabolic dysfunction-associated steatosis liver disease were counseled and referred to appropriate clinical services for further management.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}